BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 33999164)

  • 21. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
    Barrington WE; Schenk JM; Etzioni R; Arnold KB; Neuhouser ML; Thompson IM; Lucia MS; Kristal AR
    JAMA Oncol; 2015 Jun; 1(3):342-9. PubMed ID: 26181184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
    Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
    Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.
    Shore ND; Renzulli J; Fleshner NE; Hollowell CMP; Vourganti S; Silberstein J; Siddiqui R; Hairston J; Elsouda D; Russell D; Cooperberg MR; Tomlins SA
    JAMA Oncol; 2022 Aug; 8(8):1128-1136. PubMed ID: 35708696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
    Lediju O; Ikuemonisan J; Salami SS; Adejoro O
    J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.
    Kryvenko ON; Wang Y; Sadasivan S; Gupta NS; Rogers C; Bobbitt K; Chitale DA; Rundle A; Tang D; Rybicki BA
    Prostate; 2019 Jul; 79(10):1090-1098. PubMed ID: 31045267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional Outcomes After Localized Prostate Cancer Treatment.
    Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
    JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
    Cooperberg MR; Zheng Y; Faino AV; Newcomb LF; Zhu K; Cowan JE; Brooks JD; Dash A; Gleave ME; Martin F; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Carroll PR; Lin DW
    JAMA Oncol; 2020 Oct; 6(10):e203187. PubMed ID: 32852532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity.
    Underwood W; Wei J; Rubin MA; Montie JE; Resh J; Sanda MG
    Urol Oncol; 2004; 22(1):20-4. PubMed ID: 14969799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.
    Maurice MJ; Sundi D; Schaeffer EM; Abouassaly R
    J Urol; 2017 Mar; 197(3 Pt 1):627-631. PubMed ID: 27582435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
    Zagars GK; Pollack A; Pettaway CA
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.
    Nyame YA; Wilkins L; Greene DJ; Ganesan V; Dai C; Almassi N; Stephenson AJ; Gong M; Berglund R; Klein EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):617-623. PubMed ID: 30996285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five-Year Prospective Observational Study of African-American Men on Active Surveillance for Prostate Cancer Demonstrates Race Is Not Predictive of Oncologic Outcomes.
    Pincus J; Greenberg JW; Natale C; Koller CR; Miller S; Silberstein JL; Krane LS
    Oncologist; 2023 Feb; 28(2):149-156. PubMed ID: 35920550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
    Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
    World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.
    Chinea FM; Lyapichev K; Epstein JI; Kwon D; Smith PT; Pollack A; Cote RJ; Kryvenko ON
    Oncotarget; 2017 Mar; 8(13):20802-20812. PubMed ID: 28160549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
    Ross AE; Loeb S; Landis P; Partin AW; Epstein JI; Kettermann A; Feng Z; Carter HB; Walsh PC
    J Clin Oncol; 2010 Jun; 28(17):2810-6. PubMed ID: 20439642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    Parsons JK; Zahrieh D; Mohler JL; Paskett E; Hansel DE; Kibel AS; Liu H; Seisler DK; Natarajan L; White M; Hahn O; Taylor J; Hartman SJ; Stroup SP; Van Veldhuizen P; Hall L; Small EJ; Morris MJ; Pierce JP; Marshall J
    JAMA; 2020 Jan; 323(2):140-148. PubMed ID: 31935026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
    Shavers VL; Brown ML; Potosky AL; Klabunde CN; Davis WW; Moul JW; Fahey A
    J Gen Intern Med; 2004 Feb; 19(2):146-55. PubMed ID: 15009794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance.
    Kotb AF; Tanguay S; Luz MA; Kassouf W; Aprikian AG
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):53-7. PubMed ID: 20938463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.